23.62
전일 마감가:
$23.43
열려 있는:
$24.01
하루 거래량:
2.03M
Relative Volume:
1.90
시가총액:
$2.50B
수익:
-
순이익/손실:
$-150.70M
주가수익비율:
-15.24
EPS:
-1.55
순현금흐름:
$-125.67M
1주 성능:
+0.13%
1개월 성능:
+11.57%
6개월 성능:
+53.18%
1년 성능:
-16.09%
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
EWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics Inc
|
23.62 | 2.48B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Goldman | Neutral |
| 2025-07-30 | 개시 | Raymond James | Strong Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Bellevue Group AG Boosts Stock Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Wall Street analysts’ outlook for Edgewise Therapeutics Inc (EWTX) - setenews.com
Discipline and Rules-Based Execution in EWTX Response - news.stocktradersdaily.com
Schroder Investment Management Group Has $1.98 Million Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Analysts Offer Insights on Healthcare Companies: Nano-X Imaging (NNOX), Edgewise Therapeutics (EWTX) and BioNTech SE (BNTX) - The Globe and Mail
EWTX SEC FilingsEdgewise Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.4%Should You Sell? - MarketBeat
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress
XTX Topco Ltd Takes Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Sio Capital Management LLC Acquires New Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics Advances with Phase 1 Study of EDG-15400 - MSN
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
Edgewise Therapeutics (Nasdaq: EWTX) issues inducement option for 26,250 shares at $26.04 - Stock Titan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edgewise Therapeutics (EWTX) Stock Analysis Report | Financials & Insights - Benzinga
Handelsbanken Fonder AB Increases Stake in Edgewise Therapeutics, Inc. $EWTX - Defense World
Geode Capital Management LLC Raises Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Acquires 42,753 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Is Edgewise Therapeutics Inc a good long term investmentHigh Dividend Yield Stocks & High Yield Portfolio Growth - earlytimes.in
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity - Stock Titan
Edgewise Therapeutics Appoints Christopher Martin to Board - MSN
Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to "Hold" - MarketBeat
Will Edgewise Therapeutics (EWTX) Gain a Commercial Edge With Its New Board Appointment? - Sahm
Edgewise Therapeutics adds commercial biotech exec Martin to board - Investing.com
Edgewise Therapeutics adds commercial biotech exec Martin to board By Investing.com - Investing.com Nigeria
Edgewise Therapeutics Appoints Christopher Martin as Director - TradingView
[8-K] Edgewise Therapeutics, Inc. Reports Material Event | EWTX SEC FilingForm 8-K - Stock Titan
Edgewise Therapeutics appoints commercial biotech executive Christopher Martin to its Board of Directors - marketscreener.com
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin To Its Board Of Directors - TradingView
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors - WV News
What is the fair value of Edgewise Therapeutics Inc. stock now2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
What recovery options are there for Edgewise Therapeutics Inc.Quarterly Performance Summary & Accurate Trade Setup Notifications - newser.com
Multi asset correlation models including Edgewise Therapeutics Inc.Weekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
Exit strategy if you’re trapped in Edgewise Therapeutics Inc.Earnings Overview Report & Short-Term High Return Ideas - newser.com
How to track smart money flows in Edgewise Therapeutics Inc.July 2025 Breakouts & Safe Entry Point Identification - newser.com
Will Edgewise Therapeutics’ (EWTX) New CFO Mark a Shift in Its Commercial Strategy? - Yahoo Finance
Edgewise Therapeutics (EWTX): Assessing Valuation After Clinical Progress and New CFO Appointment - Sahm
What valuation multiples suggest for Edgewise Therapeutics Inc. stockPrice Action & Free Technical Confirmation Trade Alerts - newser.com
Shareholder Carruthers Files To Sell 70,000 Of Edgewise Therapeutics Inc [EWTX] - TradingView
Order flow analysis tools used on Edgewise Therapeutics Inc.GDP Growth & Weekly Top Gainers Trade List - newser.com
Edgewise Therapeutics chief business officer sells $300,300 in stock - MSN
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엣지와이즈 주식 (EWTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Nov 12 '25 |
Option Exercise |
0.18 |
100,000 |
18,000 |
123,400 |
| Russell Alan J | Chief Scientific Officer |
Nov 12 '25 |
Sale |
21.12 |
100,000 |
2,112,450 |
23,400 |
| Fox Jonathan C | Director |
Nov 11 '25 |
Buy |
18.64 |
10,700 |
199,403 |
23,702 |
자본화:
|
볼륨(24시간):